{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:10:23Z","timestamp":1777601423966,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1053\/j.ajkd.2016.07.037","type":"journal-article","created":{"date-parts":[[2016,10,22]],"date-time":"2016-10-22T16:48:22Z","timestamp":1477154902000},"page":"317-319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Bendamustine-Induced Nephrogenic Diabetes Insipidus in\u00a0a\u00a0Patient With AL Amyloidosis"],"prefix":"10.1053","volume":"69","author":[{"given":"Nsabimana A.","family":"Uwumugambi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaishali","family":"Sanchorawala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony C.","family":"Shelton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Stern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig E.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2016.07.037_bib1","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM199709253371306","article-title":"The systemic amyloidosis","volume":"337","author":"Falk","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2016.07.037_bib2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1750-1172-7-54","article-title":"AL amyloidosis","volume":"7","author":"Desport","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2016.07.037_bib3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3324\/haematol.2013.087619","article-title":"Update on treatment of light chain amyloidosis","volume":"99","author":"Mahmood","year":"2014","journal-title":"Hematologica"},{"issue":"26","key":"10.1053\/j.ajkd.2016.07.037_bib4","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1182\/blood-2013-01-453001","article-title":"Systemic light chain amyloidosis: an update for treating physicians","volume":"121","author":"Merlini","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.ajkd.2016.07.037_bib5","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1200\/JCO.2008.18.7252","article-title":"Bendamustine: rebirth of an old drug","volume":"27","author":"Cheson","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1053\/j.ajkd.2016.07.037_bib6","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","article-title":"Bendamustine in\u00a0patients with rituximab-refractory indolent and transformed non-Hodgkin\u2019s lymphoma: results from a phase II multicenter, single-agent study","volume":"26","author":"Friedberg","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.ajkd.2016.07.037_bib7","unstructured":"Treanda (bendamustine) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA Inc; September\u00a02015."},{"issue":"2","key":"10.1053\/j.ajkd.2016.07.037_bib8","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/bmt.2015.257","article-title":"Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity","volume":"51","author":"Garciaz","year":"2016","journal-title":"Bone Marrow Transpl"},{"issue":"36","key":"10.1053\/j.ajkd.2016.07.037_bib9","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment of immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1053\/j.ajkd.2016.07.037_bib10","series-title":"Clinical Physiology of Acid-Base and Electrolyte Disorders","first-page":"748","author":"Rose","year":"2001"},{"issue":"3","key":"10.1053\/j.ajkd.2016.07.037_bib11","doi-asserted-by":"crossref","first-page":"186","DOI":"10.7326\/0003-4819-144-3-200602070-00007","article-title":"Nephrogenic diabetes insipidus","volume":"144","author":"Sands","year":"2006","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1053\/j.ajkd.2016.07.037_bib12","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1053\/j.ajkd.2005.01.008","article-title":"Causes of reversible nephrogenic diabetes insipidus: a systematic review","volume":"45","author":"Garofeanu","year":"2005","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2016.07.037_bib13","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/0002-9343(60)90050-4","article-title":"Nephrogenic diabetes insipidus caused by amyloid disease: evidence in man of the role of the collecting ducts in concentrating urine","volume":"29","author":"Carone","year":"1960","journal-title":"Am J Med"},{"issue":"6","key":"10.1053\/j.ajkd.2016.07.037_bib14","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2165\/00002018-199921060-00002","article-title":"Drug-induced diabetes insipidus: incidence, prevention and management","volume":"21","author":"Bendz","year":"1999","journal-title":"Drug Saf"},{"issue":"1","key":"10.1053\/j.ajkd.2016.07.037_bib15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.ackd.2013.06.010","article-title":"Tubulointerstitial injury associated with chemotherapeutic agents","volume":"21","author":"Shirali","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1053\/j.ajkd.2016.07.037_bib16","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/ndt\/13.6.1547","article-title":"Ifosfamide-induced renal Fanconi syndrome with associated nephrogenic diabetes insipidus in an adult patient","volume":"13","author":"Negro","year":"1998","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.ajkd.2016.07.037_bib17","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1002\/PHAR.1013","article-title":"Fanconi\u2019s syndrome and nephrogenic diabetes insipidus in an adult treated with ifosfamide","volume":"32","author":"Ingemi","year":"2012","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1053\/j.ajkd.2016.07.037_bib18","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3904\/kjim.2014.29.2.246","article-title":"Ifosfamide-induced Fanconi syndrome with diabetes insipidus","volume":"29","author":"Leem","year":"2014","journal-title":"Korean J Intern Med"},{"issue":"1","key":"10.1053\/j.ajkd.2016.07.037_bib19","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/0959-8049(94)00418-5","article-title":"Nephrogenic diabetes insipidus following high dose epirubicin chemotherapy for metastatic\u00a0soft tissue sarcoma","volume":"31","author":"Vasey","year":"1995","journal-title":"Eur J Cancer"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638616304899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638616304899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T02:58:16Z","timestamp":1759460296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638616304899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0272638616304899"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2016.07.037","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bendamustine-Induced Nephrogenic Diabetes Insipidus in\u00a0a\u00a0Patient With AL Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2016.07.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}